Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
about
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.New Therapies for Hepatitis C Virus Infection.Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingFinancial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States.Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.Hepatitis C Treatment and Barriers to Eradication.Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Hepatitis C: efficacy and safety in real life.Urgency to treat patients with chronic hepatitis C in Asia.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism.Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.No longer 'written off' - times have changed for the BBV-infected dental professional.Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients.Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
P2860
Q30393824-AD8D481C-6C57-4CA1-9492-3DC7B736227AQ30841159-2B71ED19-8308-429A-ACBC-2BF2D696BBCBQ31143582-CF85E423-8422-45ED-B9B3-1F449969C5E4Q33435950-514FD74B-27D9-4E42-9006-9C7F5124DFCCQ33560181-68CC1576-1088-4530-AC16-2AD3C8F16E70Q33646482-A85F176F-566D-487F-9C1C-844A94FB414BQ33878388-05265362-FB1C-4BD4-9002-37174726371EQ36145716-5DB6182C-E98E-4C7A-B2CF-928F969C17F6Q38401928-2B401637-E476-4BC7-91F9-689A3DF71296Q38693657-AFC8B09A-5DD8-4949-AF7E-658761A25757Q38850965-6285FCA2-625C-48BB-976D-AA6D5033B7E4Q38854076-1A874A2B-0977-4E4A-A2D0-F756E1C93D64Q38961563-89E8E32B-C045-414F-AE39-2F42DEA14DFEQ39025640-1811E5D8-AD24-4159-A521-CF872E99BC60Q39032538-22CA7E14-FE9D-4BFD-8B23-E212DAB2088BQ39040719-2C2013CE-F18D-420C-84E2-1A6FAC2714EFQ39049155-FDE911F9-7987-4646-BD1C-0422F645837DQ39058953-96724C8D-346E-41E4-95C8-D7E2E6859933Q39134413-C1E2F609-68A3-4351-8C69-5D2A40A11FD2Q39254698-7A30FDE9-DEC8-4E5C-A9F0-B5542C8147FCQ39690146-042ED67A-84D1-42AE-921F-18AB3483E0B8Q40053596-A86DB7DE-593D-40F4-8E7C-C89D68C526EBQ40065692-D557226C-D606-46BF-9A6D-1C88AD1F3AD6Q40098679-64B1BC8E-6224-42C7-BC26-3E673FCB07DEQ40118666-C82B5A02-3B4E-4675-9277-1DC75A07F9B0Q40129813-C83993CA-1AF7-40E9-B014-F7EF5CFD138DQ40171277-4A63A2D2-ED46-4800-A74F-6A8D185D702AQ40176014-364FB02F-766F-4E23-90BC-A60918C0F333Q40211449-CDEA416C-4B98-467B-AB6A-1648C90A3792Q40335100-4992784E-F250-4A03-B1E0-D7A57656E899Q40335115-A3E32C27-DA94-4E57-8A91-68DC8FB5D99DQ40355278-09A6AD71-FB4C-4B74-AB5B-B1B6783FA704Q40373187-DC2ADE97-00F2-4CC7-BA57-BCD563B6AEE9Q40375140-66D4E688-A2C5-49A3-8B3D-EA63E762D053Q40469011-1BCEB4BD-FFB9-477E-8E73-799A6A3FAECDQ41923073-8DF4E7B9-1BD9-46B1-871E-0FD7C6BF4FE1Q41930106-9428F070-E527-4361-95C8-C0F0611709CFQ42370370-B61DF8C4-94DF-4AB2-A782-B568DD9211BFQ44519022-7C986C52-9A9A-46B6-9282-6BEABC00B4EEQ45325427-8F1FCCEF-1B4A-4E2C-9AC7-EF2369C8C293
P2860
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Real-world effectiveness of le ...... hepatitis C-infected patients.
@en
Real-world effectiveness of le ...... hepatitis C-infected patients.
@nl
type
label
Real-world effectiveness of le ...... hepatitis C-infected patients.
@en
Real-world effectiveness of le ...... hepatitis C-infected patients.
@nl
prefLabel
Real-world effectiveness of le ...... hepatitis C-infected patients.
@en
Real-world effectiveness of le ...... hepatitis C-infected patients.
@nl
P2093
P2860
P356
P1433
P1476
Real-world effectiveness of le ...... hepatitis C-infected patients.
@en
P2093
Larry A Mole
Pamela S Belperio
Timothy P Loomis
Troy A Shahoumian
P2860
P304
P356
10.1002/HEP.28625
P407
P577
2016-04-26T00:00:00Z